Table 1.
Main characteristics and quality of included studies
| Study ID | Country | Study type | Subjects No. (Male, %) | Subject characteristics | Age, y | Follow-up, y | Donor cell line | Labeled-cholesterol | Cholesterol acceptor | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Bauer, L, 2017 [30] | Germany | Cohort | 526 (59) | CKD | 65 ± 12 | 4.6 | J774 | 3H–cholesterol | ApoB-depleted plasma | 7 |
| Tejera–Segura, B 2017 [31] | Spanish | Cross-sectional | 401 (26) | RA | 57 ± 10 | / | J774 | BODIPY-cholesterol | ApoB-depleted plasma | 5 |
| Kopecky, C, 2016 [32] | German | Cohort | 1147 (54.8) | Hemodialysis patients | 66 | 4.1 | THP-1 | 3H–cholesterol | ApoB-depleted plasma | 7 |
| Javaheri, A, 2016 [33] | USA | Cohort | 35 (85.7) | Cardiac transplant recipients | 44 ± 4 | 2.6 | J774 | 3H–cholesterol | ApoB-depleted plasma | 6 |
| Mody, P, 2016 [34] | USA | Cohort | 1972 (44) | Free from CVD | 45 ± 9 | 9.4 | J774 | BODIPY-cholesterol | ApoB-depleted plasma | 8 |
| Liu, C 2016 [35] | China | Cohort | 1737 (65.2) | CAD | 64 | 3.8 | J774 | BODIPY-cholesterol | ApoB-depleted plasma | 6 |
| Zhang, J 2016 [36] | China | Cohort | 313 (75.4) | CAD | 66 ± 11 | 3 | J774 | 3H–cholesterol | ApoB-depleted plasma | 6 |
| Ogura, M, 2016 [37] | Japan | Cross-sectional | 227 (44.5) | Heterozygous FH | 57 ± 17 | / | J774 | 3H–cholesterol | ApoB-depleted plasma | 6 |
| Annema, W, 2016 [38] | Netherlands | Cohort | 495 (54.5) | Renal Transplant Recipients | 52 ± 12 | 7 | THP-1 | 3H–cholesterol | ApoB-depleted plasma | 8 |
| Ishikawa, T, 2016 [39] | Japan | Case-control | 258 (76.7) | CAD VS non-CAD | 66 ± 11 | / | J774 | 3H–cholesterol | ApoB-depleted plasma | 5 |
| Saleheen, D, 2015 [40] | UK | Nested case-control | 3494 (64.5) | CHD vs. non-CHD | 65 ± 8; | 6 | J774 | 3H–cholesterol | ApoB-depleted plasma | 8 |
| Rohatgi, A, 2014 [12] | Dallas | Cohort | 2924 (43) | Free from CVD | 42 | 9.4 | J774 | BODIPY-cholestero | ApoB-depleted plasma | 9 |
| Li, X M, 2013 [41] | USA | Case-control | 1150 (63.8) | CAD vs. non-CAD | 64 ± 11 | / | J774 | 3H–cholesterol | ApoB-depleted plasma | 6 |
| Khera, A V1, 2011 [29] | Caucasian | Cross-sectional | 793 (59.7) | CAD vs. non-CAD | 58 ± 10 | / | J774 | 3H–cholesterol | ApoB-depleted plasma | 6 |
| Khera, A V, 2011 [29] | Caucasian | Cross-sectional | 203 (54.2) | Healthy population | 51 ± 8 | / | J774 | 3H–cholesterol | ApoB-depleted plasma | 6 |
Notes: NOS Newcastle-Ottawa Scale, CKD chronic kidney disease, RA rheumatoid arthritis, DM diabetes mellitus, ESR erythrocyte sedimentation rate, CVD cardiovascular disease, CAD coronary artery disease, CHD coronary heart disease events, FH familial hypercholesterolemia, ApoB apolipoprotein B